News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
